MCID: CLR109
MIFTS: 42

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 11 14 16
Adenocarcinoma of Large Intestine 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0050861
NCIt 49 C5105
SNOMED-CT 68 408645001
UMLS 71 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology: 11 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to adenocarcinoma and colorectal adenoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are DNA damage response (only ATM dependent) and mTOR Pathway. The drugs Iron and Hepcidins have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and colon.

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 524)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.4 TP53 KRAS HRAS CEACAM5 CDX2
2 colorectal adenoma 32.0 TP53 MIR31 MIR18A MIR17 MIR143 KRAS
3 adenoma 31.6 TP53 KRAS HRAS CDX2
4 appendix adenocarcinoma 31.3 TP53 KRAS HRAS CEACAM5 CDX2
5 mucinous adenocarcinoma 31.3 TP53 KRAS HRAS CEACAM5 CDX2
6 colonic benign neoplasm 31.1 TP53 MIR18A MIR145 MIR143 KRAS HRAS
7 rectum adenocarcinoma 31.1 TP53 MIR143 KRAS HRAS CEACAM5 CDX2
8 rectal benign neoplasm 31.0 TP53 MIR31 MIR17 MIR145 MIR143 KRAS
9 rectum cancer 31.0 TP53 MIR31 MIR18A MIR17 MIR145 MIR143
10 bladder adenocarcinoma 30.9 TP53 CEACAM5 CDX2
11 lynch syndrome 30.9 TP53 MIR31 MIR18A MIR17 KRAS HRAS
12 gastrointestinal stromal tumor 30.8 TP53 KRAS HRAS H2AC18 CEACAM5
13 gastric adenocarcinoma 30.8 TP53 KRAS HRAS CEACAM5 CDX2
14 signet ring cell adenocarcinoma 30.7 TP53 KRAS HRAS CEACAM5 CDX2
15 exanthem 30.7 KRAS HRAS H2AC18
16 villous adenoma 30.7 TP53 KRAS HRAS CEACAM5 CDX2
17 small intestine adenocarcinoma 30.6 TP53 KRAS HRAS CDX2
18 cholangiocarcinoma 30.6 TP53 KRAS CEACAM5 CDX2
19 lung cancer susceptibility 3 30.5 TP53 MIR31 MIR17 MIR145 MIR143 KRAS
20 gastrointestinal system disease 30.5 MIR31 MIR18A MIR17 MIR145 MIR143 H2AC18
21 wilms tumor 1 30.4 TP53 KRAS HRAS H2AC18 CEACAM5
22 carcinosarcoma 30.4 TP53 KRAS HRAS
23 cystadenocarcinoma 30.4 TP53 KRAS CEACAM5
24 cystadenofibroma 30.4 TP53 KRAS HRAS
25 mismatch repair cancer syndrome 30.3 TP53 KRAS HRAS
26 lung benign neoplasm 30.3 TP53 KRAS HRAS
27 skin melanoma 30.3 TP53 KRAS HRAS H2AC18
28 li-fraumeni syndrome 30.3 TP53 KRAS HRAS H2AC18
29 diffuse large b-cell lymphoma 30.2 MIR18A MIR17 MIR145 MIR143 H2AC18
30 small intestine cancer 30.2 TP53 KRAS HRAS CEACAM5 CDX2
31 skin carcinoma 30.2 TP53 MIR31 MIR18A HRAS H2AC18
32 kidney cancer 30.2 TP53 MIR17 MIR145 H2AC18
33 colon adenoma 30.2 TP53 MIR18A MIR143 KRAS HRAS CDX2
34 stomach disease 30.2 MIR31 MIR18A MIR17 MIR145 MIR143 H2AC18
35 intrahepatic cholangiocarcinoma 30.2 TP53 MIR17 KRAS HRAS H2AC18 CEACAM5
36 gastrointestinal system cancer 30.1 MIR31 MIR18A MIR17 MIR145 MIR143 H2AC18
37 bronchiolo-alveolar adenocarcinoma 30.1 TP53 MIR17 KRAS HRAS CEACAM5 CDX2
38 oral squamous cell carcinoma 30.1 MIR31 MIR17 MIR145 MIR143 HRAS H2AC18
39 thyroid gland cancer 30.1 TP53 MIR17 KRAS HRAS H2AC18 CEACAM5
40 renal cell carcinoma, nonpapillary 30.1 TP53 MIR31 MIR18A MIR17 MIR145 MIR143
41 esophageal cancer 30.1 TP53 MIR31 MIR18A MIR17 MIR145 MIR143
42 hepatocellular carcinoma 30.1 TP53 PIM2 MIR31 MIR18A MIR17 MIR145
43 intestinal disease 30.1 TP53 MIR31 MIR18A MIR17 MIR145 MIR143
44 ovary adenocarcinoma 30.1 TP53 MIR17 KRAS HRAS H2AC18 CEACAM5
45 skin disease 30.0 TP53 MIR31 MIR18A MIR17 KRAS HRAS
46 bladder cancer 30.0 TP53 MIR31 MIR17 MIR145 MIR143 KRAS
47 squamous cell carcinoma, head and neck 30.0 TP53 MIR31 MIR18A MIR17 MIR145 MIR143
48 leukemia, chronic lymphocytic 30.0 TP53 MIR31 MIR17 MIR145 MIR143 KRAS
49 hepatoid adenocarcinoma 30.0 CEACAM5 CDX2
50 pancreatic ductal adenocarcinoma 29.9 TP53 MIR31 MIR18A MIR17 MIR145 MIR143

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 29936
2 Hepcidins Phase 4
3
Mitomycin Approved Phase 2, Phase 3 50-07-7 5746
4
Nicotine Approved Phase 3 54-11-5 942 89594
5
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
6
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
7
Chlorotrianisene Investigational, Withdrawn Phase 3 569-57-3 11289
8 Calciferol Phase 3
9 Immunoglobulins, Intravenous Phase 3
10 Immunoglobulins Phase 3
11 Antibodies, Monoclonal Phase 3
12 Antibodies Phase 3
13 Hematinics Phase 3
14 Formyltetrahydrofolates Phase 3
15 Tetrahydrofolates Phase 3
16
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
17
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
18
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
19
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
20
Cetuximab Approved Phase 2 205923-56-4
21
Vancomycin Approved Phase 2 1404-90-6 14969
22
Framycetin Approved, Experimental, Vet_approved Phase 2 1404-04-2, 119-04-0, 3947-65-7 413349 8378
23
Metronidazole Approved Phase 2 443-48-1, 69198-10-3 4173
24
Obinutuzumab Approved, Investigational Phase 1, Phase 2 949142-50-1
25
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
26
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
27
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
28
Trametinib Approved Phase 2 871700-17-3 11707110
29
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
30
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
31
Tremelimumab Approved, Investigational Phase 1, Phase 2 745013-59-6
32
Ipilimumab Approved Phase 2 477202-00-9
33
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
34
Hydroquinone Approved, Investigational Phase 2 123-31-9 785
35
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
36
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
37
Trifluridine Approved, Investigational Phase 2 70-00-8 6256
38
Tucatinib Approved, Investigational Phase 2 937263-43-9 51039094
39
Trastuzumab Approved, Investigational Phase 2 180288-69-1
40
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
41
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
42
Dopamine Approved Phase 1, Phase 2 62-31-7, 51-61-6 681
43
Metamfetamine Approved, Illicit, Withdrawn Phase 1, Phase 2 537-46-2 10836
44
Lenograstim Approved, Investigational Phase 2 135968-09-1
45
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
46
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
47
Avelumab Approved, Investigational Phase 2 1537032-82-8
48
Sulindac Approved, Investigational Phase 2 38194-50-2 5352 1548887
49
Ceritinib Approved Phase 2 1032900-25-6 57379345
50
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy Unknown status NCT03783559 Phase 3 TACE;chemotherapy±target therapy
3 A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases Unknown status NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
4 A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
5 A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
6 A Multicenter,Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma Completed NCT02390947 Phase 3 Famitinib;Placebo
7 The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial Completed NCT00265356 Phase 3
8 Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study Recruiting NCT02758951 Phase 2, Phase 3
9 Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin;Oxaliplatin
10 Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS) Recruiting NCT04094688 Phase 3 Bevacizumab;Oxaliplatin;Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Irinotecan
11 Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab Terminated NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
12 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial Withdrawn NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
13 Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
14 Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
15 A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
16 A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
17 A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-line Therapy for Patients With Metastatic Colorectal Cancer Unknown status NCT04380103 Phase 1, Phase 2 XELOXIRI/Bevacizumab
18 A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens Completed NCT00419159 Phase 2 Everolimus (RAD001)
19 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
20 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma . Completed NCT02788006 Phase 2 Regorafenib 160 mg
21 Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70 Completed NCT00104689 Phase 2 capecitabine;oxaliplatin
22 Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
23 Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease Completed NCT00890305 Phase 2 CT-011;FOLFOX
24 A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859) Completed NCT00574171 Phase 2 lapatinib;Capecitabine
25 A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
26 A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
27 A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma Completed NCT00025350 Phase 2 gefitinib
28 Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
29 A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies Completed NCT02870920 Phase 2 Tremelimumab;Durvalumab
30 Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
31 A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors Completed NCT02599324 Phase 1, Phase 2 ibrutinib;everolimus;paclitaxel;docetaxel;cetuximab;pembrolizumab
32 BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer Completed NCT02292758 Phase 2 Irinotecan
33 Regorafenib Assessment in Refractory Advanced Colorectal Cancer Completed NCT01929616 Phase 2 regorafenib
34 Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
35 A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
36 A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II) Recruiting NCT04117945 Phase 2 Irinotecan;Regorafenib
37 A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients Recruiting NCT03087071 Phase 2 Trametinib
38 A Phase 1b/2 Study of VS-6766 and Cetuximab in Patients With Advanced KRAS Mutated Colorectal Cancer Recruiting NCT05200442 Phase 1, Phase 2 VS-6766;Cetuximab
39 A Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Tyrosine Kinase Inhibitor (TKI) in Combination With Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. Recruiting NCT04483219 Phase 2 TKI ± anti-PD-1 antibody
40 Pilot Trial of Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-Responders Recruiting NCT04729322 Phase 2 Fecal Microbiota Transplantation Capsule;Metronidazole;Neomycin;Vancomycin
41 An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290, A Fibroblast Activation Protein-A (FAP) Targeted 4-1BB Ligand (CD137L), In Combination With Cibisatamab With Obinutuzumab Pre-Treatment, In Participants With Previously Treated, Metastatic, Microsatellite-stable Colorectal Adenocarcinoma With High CEACAM5 Expression Recruiting NCT04826003 Phase 1, Phase 2 RO7122290;Cibisatamab;Obinutuzumab
42 A Phase II Study Evaluating FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation Recruiting NCT03584711 Phase 2
43 Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors Recruiting NCT02185443 Phase 2
44 A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy Recruiting NCT04111172 Phase 2
45 A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Recruiting NCT04731467 Phase 1, Phase 2 CM-24 and Nivolumab - Dose Escalation;CM-24 and Nivolumab - Expansion;CM-24, Nivolumab, and Nab paclitaxel - Expansion;CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
46 A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal Cancer Recruiting NCT04457284 Phase 2 Temozolomide (TMZ);Cisplatin;Nivolumab
47 The Role of Multimodality Management in Risk-Stratified Patients With Lung-Limited Metastatic Colorectal Cancer Recruiting NCT03599752 Phase 2 Chemotherapy
48 A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine Recruiting NCT04894123 Phase 2 Trifluridine/Tipiracil;Oxaliplatin
49 CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line Recruiting NCT05312398 Phase 2 Cetuximab;FOLFIRI;FOLFOX regimen;Irinotecan
50 A Phase 1/2 Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Recruiting NCT04474470 Phase 1, Phase 2 NT219;NT219 and ERBITUX® - Dose Escalation;NT219 and ERBITUX® - Expansion

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

Organs/tissues related to Colorectal Adenocarcinoma:

MalaCards : Liver, Lymph Node, Colon, Lung, Endothelial, Thyroid, Kidney

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 4250)
# Title Authors PMID Year
1
A case of rapidly progressing and poorly differentiated Ip-type early-stage colorectal adenocarcinoma. 62
36310664 2023
2
Phytochemical profile, in vitro bioaccessibility, and anticancer potential of golden root (Rhodiola rosea L.) extracts. 62
36332586 2023
3
Topical systems for the controlled release of antineoplastic Drugs: Oxidized Alginate-Gelatin Hydrogel/Unilamellar vesicles. 62
36303362 2023
4
Germline gain-of-function MMP11 variant results in an aggressive form of colorectal cancer. 62
36093604 2023
5
Proteomic profiling reveals an association between ALDH and oxidative phosphorylation and DNA damage repair pathways in human colon adenocarcinoma stem cells. 62
36162455 2022
6
Toxicology assessment of manganese oxide nanomaterials with enhanced electrochemical properties using human in vitro models representing different exposure routes. 62
36471154 2022
7
Influence of permeability enhancers on the paracellular permeability of metformin hydrochloride and furosemide across Caco-2 cells. 62
36459686 2022
8
Krukenberg tumor in pregnancy: a rare case and review of the literature. 62
34470118 2022
9
Experimental validation of in silico analysis estimated the reverse effect of upregulated hsa-miR-106a-5p and hsa-miR-223-3p on SLC4A4 gene expression in Iranian patients with colorectal adenocarcinoma by RT-qPCR. 62
36468451 2022
10
Osteopontin expression in the invasive front stroma of colorectal adenocarcinoma is associated with tumor budding and prognosis. 62
36332325 2022
11
Major vascular reconstruction in colorectal adenocarcinoma and retroperitoneal sarcoma: A retrospective study of safety and margins in a tertiary referral centre. 62
36270156 2022
12
Efficacy of adoptively transferred allogeneic CIK cells on colorectal cancer: Augmentative antitumoral effects of GvHD. 62
36463696 2022
13
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). 62
35412430 2022
14
Cancer-associated fibroblasts derived extracellular vesicles promote angiogenesis of colorectal adenocarcinoma cells through miR-135b-5p/FOXO1 axis. 62
35100092 2022
15
Novel Ru(II)-bipyridine/phenanthroline-lapachol complexes as potential anti-cancer agents. 62
36155170 2022
16
DNA Extracted from Cytologic Slides Is a Valuable Source for PCR-Based Molecular Tests. 62
36455541 2022
17
Acteoside alleviates dextran sulphate sodium‑induced ulcerative colitis via regulation of the HO‑1/HMGB1 signaling pathway. 62
36281914 2022
18
Bioinformatics analysis on differentially expressed genes between colorectal adenoma and colorectal adenocarcinoma. 62
36031809 2022
19
Identification of odontogenic ameloblast associated as a novel target gene of the Wnt/β-catenin signaling pathway. 62
36382598 2022
20
A Canadian Provincial Screening Program for Lynch Syndrome. 62
36219179 2022
21
DNMT1 Mediated CAHM Repression Promotes Glioma Invasion via SPAK/JNK Pathway. 62
34227028 2022
22
All-trans retinoic acid enhances the anti-tumour effects of fimaporfin-based photodynamic therapy. 62
36108391 2022
23
Rectal cancer combined with abdominal tuberculosis: A case report. 62
36387825 2022
24
Antimicrobial, cytotoxic, and insulin-releasing activities of the amphibian host-defense peptide ocellatin-3N and its L-lysine-substituted analogs. 62
36426386 2022
25
Flat colorectal adenocarcinoma: a worrisome false negative of artificial intelligence-assisted colonoscopy. 62
35168276 2022
26
Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis. 62
36288643 2022
27
In vitro toxicity and internalization of gold nanoparticles (AuNPs) in human epithelial colorectal adenocarcinoma (Caco-2) cells and the human skin keratinocyte (HaCaT) cells. 62
36462792 2022
28
Antiproliferative and Microtubule-stabilizing Activities of Two Iboga-vobasine Bisindoles Alkaloids from Tabernaemontana corymbosa in Colorectal Adenocarcinoma HT-29 Cells. 62
35100653 2022
29
Colorectal adenocarcinoma with enteroblastic differentiation. Report of one case with lacunar growth pattern, microcalcifications, osseous metaplasia, and metachronous involvement of sigma and appendix. 62
36321408 2022
30
Epidermotropic Cutaneous Metastasis of Colonic Adenocarcinoma Presenting as a Sister Mary Joseph Nodule. 62
35925573 2022
31
Molecular characterization of adenocarcinomas arising in the urinary bladder following augmentation cystoplasty: a multi-institutional study. 62
36108931 2022
32
Analysis of bioactive compounds using LC-ESI-MS/MS, cytotoxic, antimicrobial effects, and enzyme activities from Cyclotrichium origanifolium. 62
36366959 2022
33
Towards personalized antibody cancer therapy: development of a microfluidic cell culture device for antibody selection. 62
36349999 2022
34
Isothiocyanate-Rich Extracts from Cauliflower (Brassica oleracea Var. Botrytis) and Radish (Raphanus sativus) Inhibited Metabolic Activity and Induced ROS in Selected Human HCT116 and HT-29 Colorectal Cancer Cells. 62
36429638 2022
35
Effects of electrospun fiber curcumin on bisphenol A exposed Caco-2 cells. 62
34696662 2022
36
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: Synthesis and pharmacological effects. 62
35904260 2022
37
Inflammatory Response in Caco-2 Cells Stimulated with Anisakis Messengers of Pathogenicity. 62
36297271 2022
38
Risk factors for small intestinal adenocarcinomas that are common in the proximal small intestine. 62
36338888 2022
39
Tuning the Cell-Adhesive Properties of Two-Component Hybrid Hydrogels to Modulate Cancer Cell Behavior, Metastasis, and Death Pathways. 62
36136959 2022
40
C. spinosa L. subsp. rupestris Phytochemical Profile and Effect on Oxidative Stress in Normal and Cancer Cells. 62
36235028 2022
41
Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer. 62
36310706 2022
42
Incidence and Survival in Synchronous and Metachronous Liver Metastases From Colorectal Cancer. 62
36239935 2022
43
Nanoplatforms for Irinotecan Delivery Based on Mesoporous Silica Modified with a Natural Polysaccharide. 62
36234345 2022
44
Chylomicron production is repressed by RPTOR knockdown, R-α-lipoic acid and 4-phenylbutyric acid in human enterocyte-like Caco-2 cells. 62
35691593 2022
45
Synthesis of 4-Hydroxycoumarin-Based Triazoles/Oxadiazoles as Novel Anticancer Agents. 62
36181443 2022
46
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges. 62
36240852 2022
47
Enhanced Antioxidant and Anti-Inflammatory Effects of Self-Nano and Microemulsifying Drug Delivery Systems Containing Curcumin. 62
36235189 2022
48
Transformer-based unsupervised contrastive learning for histopathological image classification. 62
35952419 2022
49
Effects of selected condensed tannins on Cryptosporidium parvum growth and proliferation in HCT-8 cell cultures. 62
35995247 2022
50
Predictors of Small Bowel Obstruction Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. 62
35852704 2022

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.36 MIR3184 MIR31 MIR18A MIR17 MIR145 MIR143

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 aorta smooth muscle tissue morphogenesis GO:0060414 9.26 MIR145 MIR143
2 regulation of phenotypic switching GO:1900239 9.16 MIR145 MIR143
3 positive regulation of pulmonary blood vessel remodeling GO:1905111 8.96 MIR17 MIR143
4 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.62 MIR145 MIR143

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.35 MIR31 MIR18A MIR17 MIR145 MIR143
2 mRNA 3'-UTR binding GO:0003730 9.23 UTP23 TP53 MIR31 MIR17 MIR145 MIR143

Sources for Colorectal Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....